Mesenchymal stem cells (MSCs) have affinity to tumor sites where they home, affecting their biology and growth. Previously, we have isolated mesenchymal cells from the decidua of the human placenta named as decidua-derived MSCs (DMSCs). The aims of the present study were to investigate the migration capacity of DMSCs in vitro, and in vivo in a preclinical model of mammary tumors induced by N-nitroso-N-methylurea (NMU). Additionally, we assessed the safety of DMSC administration in vivo and their effect on tumor growth. In vitro studies showed that DMSCs significantly migrate toward both, healthy human breast tissue and breast adenocarcinoma. Nevertheless, the effect on DMSC migration was significantly higher in the presence of tumor tissue. DMSCs also significantly migrated in vitro in the presence of NMU-mammary tumor homogenate when compared with control media alone. In vivo studies showed both migration and engraftment of DMSCs into NMU-induced tumors. Interestingly, DMSCs showed an inhibitory effect on the growth of primary tumors and in the development of new tumors. DMSCs did not affect the growth of secondary tumors, although secondary tumors appeared 2 weeks later, and the number of secondary tumors was lower in the DMSC-treated rats as compared with vehicle-treated rats. To our knowledge, this is the first report showing placental MSCs effect on tumor growth. In conclusion, DMSCs could serve as a therapeutic agent themselves and as a cellular vehicle of anticancer drugs.
INTRODUCTION
Estrogen is a hormone with an essential function during normal growth and development of the breast and tissues involved in reproduction. However, estrogen is also associated with an increased risk for breast cancer in women. 1, 2 Treatments for breast cancer have been based on blocking the estrogen receptor in estrogen receptorpositive patients. 3, 4 However, some estrogen receptor-positive patients do not respond to the hormonal treatment. 5, 6 Chemical mammary carcinogenesis is a multi-step process consisting of initiation, promotion and progression stages. The water soluble compound N-nitroso-N-methylurea (NMU) elicits mammary hormone-dependent cancer with high incidence in certain rat models. 7, 8 NMU readily induces mammary cancer in sensitive rat strains such as Sprague-Dawley and more resistant rats such as Wistar, using repeated doses of the carcinogen. 9, 10 There is some evidence to suggest that NMU animal model mimics human breast cancer in many aspects, such as histopathology, cellular origin, hormone dependency, gene expression profiling and molecular alterations. [11] [12] [13] [14] [15] [16] Human mesenchymal stem cells (hMSCs) are pluripotent progenitor cells that contribute to the maintenance and regeneration of a variety of connective tissues, including bone, fat, cartilage and muscle. 17 Since these cells have a high tropism for injury sites, they have been proposed as cellular vehicles for anticancer drugs to graft onto tumors reducing the side effects and the doses administered to patients. [18] [19] [20] MSCs have affinity for tumors where they home, affecting their biology and growth. In addition, hMSCs possess the ability to proliferate without differentiation and under appropriate stimuli to differentiate into cell types of mesenchymal and non-mesenchymal origin and contribute to tissue repair and wound healing. 21 MSCs also show immunosuppressive properties allowing their therapeutic use in allogeneic settings. 22, 23 Adult MSCs are normally isolated from bone marrow and adipose tissue. However, their isolation procedure from both tissues is invasive; the cells being present in low quantities, and the number, proliferation and differentiation capacities decline with donor age. We have recently described an additional source of MSC without invasive procedures, the human term decidua. 24 These cells named as decidua-derived MSCs (DMSCs) showed high proliferation and differentiation capacity into cells from the three embryonic layers. Besides, DMSCs are adult stem cells without the ethical concerns of embryonic stem cells, which can be cryopreserved, have a low risk of viral infection and low or nonimmune response, and also exhibit genomic stability under extended culture periods suggesting that DMSCs could be a safe product for future clinical applications.
Cellular migration has an important role during development and in wound healing. Tumor microenvironments resemble wound environments and can be considered as unhealed wounds. 25 Tumor microenvironments are a continuous source of chemokines and cytokines that attract MSCs inducing their migration. The use of hMSCs as cellular vehicles for tumor therapies is a relevant issue. hMSCs migrate and home to tumors affecting their biology via secretion of stromal factors and paracrine signaling. 26, 27 Although several studies have shown conflicting findings on the effects of hMSCs at the tumor site, the interest of using this type of cells as cellular vehicles in cancer therapy has increased recently.
The aim of this study was to evaluate the in vitro and in vivo migration and the engraftment potential of DMSCs into NMUinduced mammary tumors. At the same time, we sought to evaluate the safety of in vivo DMSCs administration and their biological effect to assess the possible use of DMSCs as a therapeutic agent itself and as cellular vehicles for local delivery of anticancer drugs in tumor therapies. This is the first report showing that placental MSCs affect the tumor progression and could serve as cellular vehicles of anti-breast cancer drugs. 8 Briefly, for the induction of mammary carcinomas, 5 mg per 100 g body weight of NMU (SigmaAldrich, Madrid, Spain) was administered once a week during 2 weeks by intraperitoneal injection. In addition, metoclopramide (0.125 mg l À 1 ), a dopaminergic antagonist, was administered to the drinking water during the duration of the experiment to induce hyperprolactinemia in the rats 28 to increase the incidence of tumors per rat and shorten the initiation time, as demonstrated previously. 8 Animals were palpated weekly for detection of mammary tumors.
MATERIALS AND METHODS
Tissue homogenates from rat NMU-induced tumors and human healthy and tumor breast tissue Tumors were dissected out under anesthesia and rats were killed by anesthesia overdose. Tumors were weight and stored immediately at À 80 1C until use. Tumor homogenates were performed at 4 1C. Tissues were washed in ice-cold phosphate-buffered saline buffer (pH 7.4) and then homogenized in the same buffer (5 g of wet tumor per 10 ml). The homogenate was isolated by centrifugation for 30 min at 9000 g and the supernatant was stored in aliquots at À 80 1C until use.
Human healthy and tumor breast samples were obtained by biopsy at the Department of Obstetrics and Gynecology under informed consent approved by the Ethics Committee from Hospital Universitario 12 de Octubre, Madrid, Spain. Tissue homogenates were prepared as described above for NUM-induced tumor samples. To standardize the amount of protein in each sample from the different tissues and conditions, the protein concentration was measured using the Lowry protein assay kit (Bio-Rad, Madrid, Spain) following the manufacturer instructions.
Culture of rat mammary adenocarcinoma, NMU cell line Rat NMU cell line was obtained from American Type Culture Collection (Manassas, VA, USA, http://www.atcc.org) and cultured in Eagles Minimum Essential Medium supplemented with 10% fetal calf serum and 1% penicillin-streptomycin. At confluence, cell homogenate was prepared as described above for tissue samples. Total protein concentration was determined as described above.
Culture of normal human dermal fibroblast
Normal human dermal fibroblast from human adult skin was purchased from Lonza (Basel, Switzerland) and cultured in FGM-2 BulletKit (Lonza) as suggested by the manufacturer.
Isolation and culture of DMSCs
Human placentas were obtained from the Department of Obstetrics and Gynecology from healthy mothers during natural or cesarean births under written informed consent approved by the Ethics Committee from Hospital Universitario 12 de Octubre. The placentas used to isolate the cells are always obtained from healthy mothers tested for HIV, HCV and HBV and without any other disease. Processing of placental membranes and culture of primary cells was done as previously described. 24 Briefly, extraembryonic membranes (amnion, chorion and decidua) were processed by enzymatic digestion. Isolated cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM of glutamine, 0.1 mM of sodium pyruvate, 55 mM b-mercaptoethanol, 1% non-essential amino acids, 1% penicillin/streptomycin, 10% fetal bovine serum and 10 ng ml À 1 of EGF (epidermal growth factor), at 37 1C, 5% CO 2 and 95% humidity. Nonadherent cells were discarded after 5 days. In our preceding study, we reported the morphology, phenotype and MSC characteristics of DMSCs. 24 At confluence, adherent cells were passaged and seeded at a density of 4-5 Â 10 4 cells per cm 2 .
Histology
For diagnosis of mammary gland cancer, palpable tumors were dissected out and the NMU-induced tumors were analyzed by histological examination of paraffin sections stained with hematoxylin/eosin and by light microscopy of 5 mm-thick sections of frozen tissues cut on a cryostat. The tumors were tested, and diagnosed separately by two different pathologists.
In vitro and in vivo migration capacity assay of DMSCs
The in vitro effect of mammary tumor homogenate on the DMSC migration capacity was determined using 24-well transwell Boyden chambers with 8 mm pore polycarbonate membranes. The migration was then evaluated by the CytoSelectt 24-Well Cell Migration Assay (8 mm, Colorimetric, Cell Biolabs, Bionova Cientifica, S.L., Madrid, Spain). Briefly, 0.5 Â 10 6 DMSCs in 300 ml of migration media (DMEM supplemented with 2 mM of glutamine, 0.1 mM of sodium pyruvate, 55 mM b-mercaptoethanol, 1% non-essential amino acids) were seeded in the upper chamber of the transwell system. NMU-tumor homogenate in migration media was added in the lower part of the well at a protein concentration of 0.05-2 mg ml À 1 . Migration medium without tissue was used as a negative control. Migration was assessed at 1.5, 3 and 6 h. Non-migratory cells were removed from the top of the membrane and migratory cells on the bottom of the polycarbonate membrane, were stained with the Cell Stain Solution and quantified according to manufacturer's instructions. Migratory cells were visualized (three individual fields per insert) using a light microscope under Â 40 magnification objective. Finally, color of stained cells was subsequently extracted with the Extraction Solution, and quantified by absorbance at 560 nm using a Multiskan Ex plate reader (Thermo Electro Corporation, Nirco, Madrid, Spain). All experiments were done as a minimum in tripiclate.
To evaluate the in vivo migration capacity of DMSCs, 1.5 Â 10 6 cells were labeled with PKH26 Red Fluorescent Cell Linker Kit (Sigma-Aldrich), a dye used for general cell membrane labeling. PKH26-labeled cells were infused into the circulation of competent recipient rats with mammary tumors through tail-vein injection. Twenty-four and seventy-two hours later, rats were anesthetized, mammary tumors, liver and lungs were removed and stored at À 80 1C until use. Frozen tissue was sectioned in the cryostat, nucleus were stained DAPI (4 0 ,6 0 diamidino-2-phenylindole) (SigmaAldrich) for 1 min and sections were visualized by fluorescence microscopy in a Leica DMIL microscope (Leica Microsistemas, S.L.U., Barcelona, Spain). To evaluate the observed distribution of red-positive cells in different tissues, a semiquantitative system was used.
Inmunostaining
Tissues sections were fixed with 10% formalin for 30 min at room temperature and permeabilized with 0.3% Triton X-100 for 10 min. Nonspecific binding was blocked by 5% horse serum. Primary antibody anti-human nuclei (Millipore Iberica S.A.U., Madrid, Spain) was incubated DMSCs migrate and inhibit breast tumor growth I Vegh et al overnight at 4 1C, rinsed with phosphate-buffered saline twice and incubated with FITC-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, Vitro SA, Madrid, Spain). Tissues were mounted in VECTASHIELD Mounting Media with DAPI to counterstain the nucleus (Vector Laboratories, Burlingame, CA, USA).
Analysis of biological effects of DMSCs administration
To evaluate the in vivo effect of DMSCs, 1.5 Â 10 6 DMSCs were injected weekly into the tail vein for five consecutive weeks as soon as primary tumors were detected. Measurement of tumor size (length Â width, mm 2 ) was carried out weekly using a caliper. After detection, secondary tumors were also measured weekly. The animals were killed at week 10 and the number of tumors, weight and volume (length Â width Â high, mm 3 ) were analyzed.
Statistical analysis
The data were expressed as the mean±s.e.m. Inter-group statistical significance was performed with the unpaired Student's t-test. Values with Po0.05 were considered as statistically significant.
RESULTS
Bone marrow-derived MSCs (BM-MSCs) are able to migrate and home at tumor sites with high efficiency. DMSCs are mesenchymal cells and their in vitro migration capability was analyzed in the presence of normal and tumor human breast homogenate. The results showed that in the presence of migration medium (C) used as a negative control, DMSCs did not migrate ( Figure 1 ). There was no difference in the optical density obtained in control medium compared with the Extraction Solution (B). However, there was a significant increase in DMSC in vitro migration toward human healthy breast homogenate (H) when compared with control media. Interestingly, DMSC migration was significantly enhanced in the presence of human breast tumor (T) from the same patient. These results clearly suggest that some chemoattractants present in the tumor homogenate are responsible for the significantly higher DMSC chemo-attraction toward the tumor tissue compared with control and healthy breast tissue from the same patient. NMU-induced tumors are similar to human hormone-dependent breast cancer and could serve as an animal model of mammary carcinogenesis. The histological evaluation of rat NMU-induced mammary tumors revealed that all the tumors analyzed were adenocarcinomas (Figure 2 ). Microscopically, we observed mammary hyperplasia with an increase in the layers of epithelial cells and further epithelial differentiation with pale secretion material. Epithelial cells were very solid small cells with round, homogeneous and hyperchromatic nuclei that generally lacked nucleoli (Figure 2a) . Neoplastic cells formed gland-like structures that were very clearly bounded and rigidly confined by the adjacent stroma resembling a ductal carcinoma in situ (Figure 2b) .
To investigate whether DMSCs have tropism for rat mammary tumors, in vitro transwell cell migration assays were performed in the presence of NMU-induced tumors homogenate. We wanted to study the effect of live tissue on the migratory capacity of DMSCs. However, the gland-like structure of rat mammary tumors is soft tissue surrounded by a hard capsulate. This kind of structure is very difficult to cut in the vibrotome without disrupting the architecture of the tissue to maintain the cells alive. So, as with human tissue, migration assays were done with rat mammary tumor homogenates and compared with control migration medium as negative control (Figure 3 ). DMSCs did not migrate in the presence of migration medium (Figure 3aA ). DMSCs presented a significant migration toward different protein concentrations (0.05, 0.25, 0.5, 1.0 and 2.0 mg ml À 1 ) of NMUtumor homogenate at 3 h (Figure 3aB-F) . Quantification of the in vitro migration at different concentrations of tumor homogenate showed a significant increase in migration at all time points assayed (1.5, 3 and 6 h, Figure 3b) . Interestingly, the chemoattraction of DMSCs by rat tumor tissue homogenate was similar at the different concentrations assayed at each time point. This migration was also statistically significant at a concentration of homogenate as low as 0.05 mg ml À 1 of total protein (Figure 3aB ; Figure 3c ). These results suggest that NMU-induced tumors should also contain some chemo-attractants that induce in vitro migration of DMSCs. Subsequently, NMU-induced tumors in rats could serve as an animal model of mammary carcinogenesis to evaluate the possible use of DMSCs as anti-tumor drug delivery vehicles.
DMSC migration capacity in the presence of isolated NMU cell line homogenate was also analyzed. NMU-induced tumor homogenate and normal human dermal fibroblast homogenate were used as positive and negative controls, respectively (Figure 3d ). All samples were adjusted at 0.5 mg ml À 1 of total protein concentration. A significant migration of DMSCs in the presence of normal human dermal fibroblast homogenate (F) was observed when compared with control migration in the presence of medium without tissue homogenate (C). However, in vitro migration of DMSCs in the presence of NMU cell line homogenate (N) or in the presence of rat NMU-induced tumor homogenate (T) was also statistically significant and threefold higher with respect to the migration in the presence of fibroblasts. These results suggested that factors present in NMU cell line and in NMUinduced tumors significantly affect the migration of DMSCs.
For the in vivo migratory capacity and homing of DMSCs into NMU-induced mammary tumors in rats, red fluorescent-labeled DMSCs (Figure 4a) were injected into the tail vein of several NMUinduced tumor rats. Tumors, liver and lungs were surgically removed at 24 and 72 h and the presence of red-fluorescent cells was examined by fluorescent microscopy ( Figure 4 ; Table 1 ). PKH26 is a dye used for general cell membrane labeling because it is composed of long aliphatic tails that are stably incorporated into the lipids of the cell membrane. According to the manufacturer, labeled cells can be visualized as bright immunofluorescent cells, as well as cells with a punctate or patchy appearance. Figure 4b shows this punctated/patchy appearance of DMSCs cultured in vitro. Red fluorescent cells were observed in Figure 1 . Decidua-derived mesenchymal stem cells (DMSCs) migrate in the presence of healthy and breast tumor homogenate. B, the mean optical density (OD) of the Extraction Solution (n ¼ 6); C, DMSCs did not migrate in the presence of control culture medium (Dulbecco's modified Eagle's medium (DMEM)) alone (n ¼ 10). The mean OD of C was not statistically significant with respect to B ( # P ¼ 0.5). In the presence of both healthy human breast tissue (H, n ¼ 6) and human breast adenocarcinoma tissue (T, n ¼ 6), DMSC migration at 3 h was statistically significant with respect to control (C) (*Po0.0005). DMSC migration in the presence of breast adenocarcinoma tissue (T) was higher than both control and healthy breast tissue (**Po0.025). The migration in the presence of DMEM alone was used as control (C, n ¼ 10). DMSC in vitro migration was statistically significant with respect to C at the different concentrations assayed (0.25, 0.5, 1.0 and 2.0 mg ml À 1 total protein) at 1.5 h (**Po0.025; n ¼ 7 at each concentration), at 3 h (*Pp0.0005, n ¼ 7, 8, 10 and 7 at each concentration, respectively) and at 6 h (**Po0.025; n ¼ 7 at each concentration). (c) DMSC in vitro migration capacity at 3 h was statistically significant even in the presence of a very low concentration of NMU-tumor homogenate (0.05 mg ml À 1 protein concentration, n ¼ 2) (*Po0.0025). (d) Quantification of DMSC in vitro migration in the presence of NMU cell line homogenate. DMSC migration capacity for 1.5 h in the presence of 0.5 mg ml À 1 total protein of isolated rat NMU cells homogenate was analyzed. As positive and negative controls, NMU rat tumor homogenate and human dermal fibroblast were used, respectively. Migration in the presence of DMEM alone used as negative control (C, n ¼ 15); DMSC migration in the presence of healthy human dermal fibroblast homogenate (F, n ¼ 3, *Po0.005); DMSC migration in the presence of isolated NMU cell line homogenate (N, n ¼ 3, **Po0.0005); DMSC migration in the presence of NMU-induced tumor rat homogenate (T, n ¼ 3; ***Po0.0025). (Figures 4c and d) . Punctuate or patchy appearance red-positive cells inside the tumors are shown in two closer images (Figures 4e and f) . We also examined the trafficking of DMSCs to other organs such as lungs and liver. Semiquantitative measurement at 24 h shows that the lungs accumulate the highest amount of cells whereas in tumor and liver the number of cells was lower (Table 1) . At 72 h, there was an increase in the number of fluorescent DMSCs in the liver although the increase was significantly higher in the tumor. In the lungs, labeled cells were practically undetectable at this time. In addition, to verify the human origin of the fluorescent cells, immunodetection of a human nuclear antigen was carried out on a tumor section using an anti-nuclei antibody. The results showed colocalization of red fluorescence of the PKH26 staining with the green fluorescence of the FITC labeling of human nuclei (Figures 4g-i) . The results indicate that intravenously (i.v.) injected DMSCs display specific tropism and homing for the NMU-induced mammary tumors in vivo and subsequently, could be used as anti-tumor drug delivery vehicles for the treatment of breast cancers.
Owing to the contradictory published results on the effects of hMSCs at the tumor site, we tested the biological effect of DMSC administration on mammary tumor progression. DMSCs were i.v. injected once per week for 5 weeks. The results showed that in vivo DMSC injection have an important effect on the evolution and progression of the NMU tumors ( Figure 5 ). Tumor size of primary tumors was significantly lower throughout the course of the experiment in the DMSC-injected rats compared with control rats (Figure 5a, left panel) , and particularly at the end of the experiment (*Po0.0125). Tumor growth was faster in control rats than in DMSC-treated rats. In fact, in the control rats the tumor size with respect to initial size was significantly higher just 2 weeks after the first injection while in DMSC-treated rats, the size was not statistically significant 5 weeks later. Moreover, additional tumors appeared 2 weeks later in the DMSC-transplanted rats compared with control rats and the initial size of these tumors was lower (Figure 5a, right panel) . At the end of the experiment, the total number of tumors was significantly higher in the control rats vs. DMSC-treated rats (Figure 5b ). In fact, the vehicle-treated rats had a minimum of one secondary tumor, while in the DMSC-treated group only two rats had a secondary tumor ( Table 2 ). The volume and weight of primary tumors was also significantly lower in the DMSC rats (Figures 5c and d, respectively) . However, volume and weight of secondary tumors was similar in both groups of rats. Taken together, these data suggest that DMSCs have a significant role in inhibiting primary tumor progression and in the appearance of secondary tumors and could be used as a therapeutic agent for the treatment of breast cancer besides their use as cellular vehicles.
DISCUSSION
The mechanisms and the soluble factors involved in the BM-MSC migration are not well known at present. 29, 30 The data presented here demonstrated the in vitro and in vivo tropism of DMSCs to tumors. The absence of DMSC-homogenate contact suggests that 
Abbreviation: DMSCs, decidua-derived mesenchymal stem cells. In vivo decidua-derived mesenchymal stem cell (DMSC) administration to N-nitroso-N-methylurea (NMU) rats has an important effect in the progression of the tumors. (a) Five consecutive doses of DMSCs or vehicle were administered intravenously (i.v.) into the tail vein of NMU-induced rats (arrows). First injection was considered as week 0. Tumor growth was measured during the administration of the cells and for five additional weeks. Tumor size in mm 2 of primary tumors was significantly lower in the DMSC-injected rats compared with control rats (left panel), and particularly at the end of the experiment (*Po0.0125). Tumor size was significantly higher with respect to initial size 2 weeks after the initial injection in the control rats (#) and 5 weeks in the DMSC-treated rats (z). Secondary tumors appeared 2 weeks later in the DMSC-injected rats (right panel). (b) Number of tumors at the end of the experiment was significantly higher in the control rats. (c) Volume in mm 3 of primary tumors was significantly lower in the DMSC rats compared with control rats at the end of the experiment. Secondary tumors were similar in both groups of rats. (d) Tumor weight of primary tumors was significantly lower in DMSC-treated rats whereas there was no significant difference in the weight of secondary tumors. the migration mechanism of the DMSCs is probably mediated by soluble factors present in the tumor homogenate that cross the trans-well membrane. Interestingly, in the presence of human healthy breast tissue there is a significant migration of these cells, indicating that DMSCs have a high affinity for breast tissue and this migration is increased in the presence of tumor breast tissue from the same patient. Local cytokines and other factors present in the tumor cells, the tumor microenvironment or in the inflammatory surrounding tissue may contribute to the high migratory capacity of DMSCs in the presence of tumor tissue. 29, 30 Indeed, the suppression of the inflammatory microenvironment of pancreatic tumors by an anti-inflammatory agent generate a reduction in the homing of BM-MSCs into the tumors, and as a consequence, a decrease in the tumor inhibition observed in the mice injected with MSCs alone or MSCs expressing interferon b.
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Whether the migratory capacity of DMSCs could be decreased by the suppression of the inflammation in the breast tumor tissue needs to be addressed. NMU-induced tumors are similar to human hormone-dependent breast cancer and could serve as an animal model of mammary carcinogenesis. 32 In line with previous data published by us and other groups, the results presented here suggest that rat NMU-induced tumors were adenocarcinomas with a high histopathological resemblance to human breast tumors. 8, [14] [15] [16] 32 In addition, NMU-induced tumors have some chemo-attractants that induce the in vitro migration of DMSCs, suggesting that NMUinduced tumors in rats could serve as an animal model of mammary carcinogenesis to evaluate the possible use of DMSCs as anti-tumor drug delivery vehicles.
Human MSC is a very well-defined cell population of adult stem cells in vitro but its biology in vivo is poorly understood. 33, 34 Several studies have shown that exogenously administered MSCs can migrate to sites of injury. 29, [35] [36] [37] [38] Different receptors as well as inflammatory factors, including chemokines, cytokines, growth factors and extracellular matrix, have been involved in the migration and homing of hMSCs to wound site inflammation or tumor environments. 29, 39, 40 However, the migration mechanism involved in each of these injured situations remains to be elucidated.
Due to the difficulty in using live sliced tissue, we used human breast and rat mammary tumor homogenates in the migration experiments assuming that during breast tumor growth some molecules and debris would be released to the microenvironment and would have some effect on the migration and homing of DMSCs to the tumor. 41 Indeed, DMSCs migrated in the presence of healthy human breast tissue and this migration is increased in the presence of breast tumor tissue homogenate from the same donor, indicating that injured tissue increases the migration capacity of DMSCs to the tumor area. Previously, Montzka et al. 41 also used tissue homogenate to study the migration capacity of BM-MSCs in the presence of healthy or damaged heart and spinal tissue, but did not observe any difference in the migration activity. 41 Several reasons could be involved in this different behavior. First, BM-MSCs are a more heterogeneous population than DMSCs, 24 and these cell populations are probably different in their migratory capabilities. 30, 42 Second, a different migration assay was used that could explain the different migration potential between both populations. Third, the migration media used was supplemented with several growth factors (bFGF, EGF and PDGF-BB) that could mask the effect of the damaged tissues. Finally, we used tumor tissue indicating the possibility that different types of injury/damage could induce a different response in these two different types of MSCs. Additionally, the chemotactic molecules secreted by the surrounding stroma, the tumor cells themselves also secreted cytokines and chemotactic molecules. Isolated NMU-tumor cell line and tumor tissue homogenate did not show a significantly different chemotaxis-induction potential on DMSC migration capacity. Interestingly, this migration potential was significantly higher when compared with fibroblast homogenate. These data suggest that factors present on the surface of the tumor cells, or released by them, are the main factors responsible for the high tropism of DMSCs toward NMUinduced mammary tumors. Our results suggest the possibility that DMSCs possess properties to be used as cellular vehicles for targeted estrogen-dependent breast cancer therapy.
Intravenously injected DMSCs were localized into mammary tumors in vivo, indicating that DMSCs engraft into breast tumor sites. We studied the trafficking of DMSCs to other organs after intravenous administration. At 24 h, DMSCs were detected in the tumor; however, the lungs accumulate the largest number of cells. At 72 h, the number of fluorescent cells was increased in the liver and primarily in the tumor, while they were practically undetectable in the lungs. This biphasic distribution of MSCs, with early accumulation in lung and later major accumulation in liver and injured tissue has been described previously. [43] [44] [45] The tropism and migratory capacity of BM-MSCs for breast cancer has been previously reported in a xenograft model of breast carcinoma in severe combined immunodeficiency (SCID) mice. 46 These immunocompromised mice models have doubtful relevance for future application to human diseases because the effect of the immune system on MSC migration and engraftment was not taken into account. 47 Here, we injected human cells in an immunocompetent rat. DMSCs i.v. injected were capable of migration and homing to mammary tumors without rejection. Therefore, we assessed the safety of the DMSCs assuming that the use of DMSCs could be safe and feasible for human patients in future clinical trials.
DMSC-based anticancer therapies represent an exciting and novel therapeutic approach, but a better understanding of how DMSC home and engraft within the tumors and whether they would have an impact on tumor behavior is essential before DMSC-based delivery systems can be used in a clinical setting. Therefore, we tested their biological effect when injected i.v. into the tumor rats. In vivo DMSC administration into NMU-tumor rats have an important effect on the growth of primary tumors as well as preventing and delaying the emergence of new tumors, suggesting a therapeutic role of DMSCs in breast cancers. Although, in the DMSC-treated rats, there was a reduction in the number of secondary tumors and their appearance was delayed for 2 weeks, the size of secondary tumor growth increases rapidly and this coincides with the end of DMSC injection. Whether the repeated treatment of DMSCs would totally inhibit the appearance of secondary tumors and their growth, it is an aim to be addressed. Several reports have described hMSCs as having an inhibitory effect of several tumors while several others showed a direct involvement of MSCs in the tumor progression. 48 Several factors can contribute to these contradictory reports, such as the different source of the MSCs, the heterogeneity of some of the MSC populations, the different approaches to tumor development, as well as the dose, timing and route of administration of MSCs. To be able to compare the different results, a more homogeneous population of MSCs should be obtained. 48 DMSCs are a very Abbreviation: DMSCs, decidua-derived mesenchymal stem cells.
homogenous population of MSCs. 24 Therefore, the results obtained here could be clinically relevant, due to the homogeneous population of stem cells administered together with the robust rat model of disease used, that is, the pathology is similar to human disease and is an immunocompetent model.
MSCs of any source are very important adult stem cells for use in allogeneic transplants because of their immunomodulatory and immunosuppressive properties. DMSCs, as well as BM-MSCs, do not express major histocompatibility complex class II and the T-cell co-stimulatory molecules, suggesting that they are immunoprivileged cells which can be tolerated in allogeneic transplantation. 24 Several articles describe the use of MSCs without any adverse reaction of graft-versus-host disease (GVHD) or hostversus-graft disease (HVGD). 18, 22, 23, 27, 29, 31, 35 As a control of the possible xenogenic adverse response, we injected DMSCs in five healthy rats and did not observe any adverse immunologic response, GVHD or HVGD, in the animals (data not shown). These results confirm the immunoprivileged capacity of DMSCs in a xenograft model. Similar results were obtained in immunocompetent C57/B6 mice (data not shown). In conclusion, the effect of DMSCs slowing down the tumor growth is specific and not because of an innate inflammatory response, that therefore slows the tumor growth.
The therapeutic potential of hMSCs as therapeutic agents as well as cellular vehicles of anti-tumoral agents is an area of great excitement and promise for the more effective action of the therapeutic drugs at the site of tumors avoiding some of the side effects of actual clinical therapies. 18, 35, 49 In conclusion, DMSCs were attracted toward both rat and human breast tumors. Additionally, DMSCs migrated in vivo to rat tumors having an important effect in slowing down the tumor growth of the primary tumors and the appearance of secondary tumors, suggesting that DMSCs could have a future clinical use in humans as therapeutic agents themselves and as cellular vehicles for the delivery of anticancer drugs in the treatment of breast tumors.
